Company Profile
Cogent Biosciences Stock Price, News & Analysis
- Ticker:
- COGT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
41.80 USD (-1.11%)
Close
Last updated: August 6, 2026
5.6B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, COGT closed down 1.11% at $41.80. No new same-company headline was identified in the current news window.
Company overview
Genetically Defined Diseases
Cogent Biosciences develops precision therapies for diseases driven by defined oncogenic mutations. Its portfolio is led by a selective KIT inhibitor and includes earlier programs directed at ErbB2, PI3Kα, KRAS and JAK2.
Bezuclastinib
Bezuclastinib is designed to inhibit KIT D816V and other exon 17 KIT mutations while limiting off-target activity. These mutations drive systemic mastocytosis and are also important resistance mechanisms in gastrointestinal stromal tumors.
Systemic Mastocytosis Franchise
The company is pursuing bezuclastinib in both non-advanced and advanced systemic mastocytosis. An NDA for non-advanced disease is under FDA review, while the APEX program supports a separate planned application in advanced disease.
Gastrointestinal Stromal Tumors
The Phase 3 PEAK trial supports an NDA for bezuclastinib in GIST after prior imatinib treatment. Cogent also plans to study bezuclastinib with sunitinib in first-line exon 9-mutant GIST, potentially extending use into an earlier treatment setting.
Early Precision-Oncology Pipeline
CGT4255 is a brain-penetrant ErbB2 inhibitor and CGT6297 is a selective PI3Kα inhibitor, both in Phase 1 studies. Preclinical candidates CGT1815 and CGT1145 target pan-KRAS(ON) and JAK2 V617F, respectively.
Future catalysts
Detailed Phase 3 PEAK data to be presented at ASCO on May 30, 2026.
Submission of the APEX NDA for advanced systemic mastocytosis planned in the first half of 2026.
Initiation of a Phase 2 bezuclastinib-plus-sunitinib trial in first-line exon 9-mutant GIST planned in the first half of 2026.
Potential bezuclastinib launches in GIST and systemic mastocytosis in the second half of 2026, subject to approval.
FDA action on the non-advanced systemic mastocytosis NDA expected by December 30, 2026.
IND submissions planned for CGT1815 and CGT1145.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cogent Biosciences (COGT)?
Cogent Biosciences (COGT) most recently closed at 41.80 USD, a -1.11% move versus the previous session.
What is the market cap of Cogent Biosciences (COGT)?
Cogent Biosciences currently has a market capitalization of 5.6B USD on BioPharmSignal.
What does Cogent Biosciences do?
Genetically Defined Diseases Cogent Biosciences develops precision therapies for diseases driven by defined oncogenic mutations. Its portfolio is led by a selective KIT inhibitor and includes earlier programs directed at ErbB2, PI3Kα, KRAS and JAK2. Bezuclastinib Bezuclastinib is designed to inhibit KIT D816V and other exon 17 KIT mutations while limiting...
On which exchange is COGT stock listed?
Cogent Biosciences (COGT) is associated with NASDAQ, United States, Biopharma.
What is bezuclastinib?
Initiation of a Phase 2 bezuclastinib-plus-sunitinib trial in first-line exon 9-mutant GIST planned in the first half of 2026.
Which conditions is Cogent Biosciences targeting with bezuclastinib?
Cogent Biosciences is associated with oncology, genetic disease based on its company overview and current catalyst commentary.
How does Cogent Biosciences describe recent progress with bezuclastinib?
Initiation of a Phase 2 bezuclastinib-plus-sunitinib trial in first-line exon 9-mutant GIST planned in the first half of 2026.
What is imatinib?
Gastrointestinal Stromal Tumors The Phase 3 PEAK trial supports an NDA for bezuclastinib in GIST after prior imatinib treatment.